A high-dose aminoglycoside regimen combined with renal replacement therapy for the treatment of MDR pathogens: A proof-of-concept study

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 5, 2016, Pages 1386-1394

  Brasseur, Alexandre ^a   Hites, Maya ^a   Roisin, Sandrine ^a   Cotton, Frédéric ^a   Vincent, Jean Louis ^a   De Backer, Daniel ^a   Jacobs, Frédérique ^a   Taccone, Fabio Silvio ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; GENTAMICIN; TOBRAMYCIN; ANTIINFECTIVE AGENT;

ABDOMINAL INFECTION; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; CONTINUOUS HEMODIAFILTRATION; DRUG BLOOD LEVEL; DRUG MEGADOSE; FEMALE; GRAM NEGATIVE SEPSIS; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; MINIMUM PLASMA CONCENTRATION; MULTIDRUG RESISTANCE; PATHOGEN CLEARANCE; PSEUDOMONAS INFECTION; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; TREATMENT RESPONSE; CRITICAL ILLNESS; GRAM-NEGATIVE BACTERIAL INFECTIONS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; RENAL REPLACEMENT THERAPY; SEPSIS; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CRITICAL ILLNESS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDIES; SEPSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84965065646     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv491     Document Type: Article

References (38)

1. Obritsch MD, Fish DN, MacLaren R et al. Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options. Pharmacotherapy 2005; 25: 1353-64.
2. Shorr AF. Review of studies of the impact on Gram-negative bacterial resistance on outcomes in the intensive care unit. Crit Care Med 2009; 37: 1463-9.
3. Falagas ME, Bliziotis IA. Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era? Int J Antimicrob Agents 2007; 29: 630-6.
4. Page MG, Heim J. Prospects for the next anti-Pseudomonas drug. Curr Opin Pharmacol 2009; 9: 558-65.
5. Falagas ME, Kopterides P. Old antibiotics for infections in critically ill patients. Curr Opin Crit Care 2003; 13: 592-7.
6. Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004; 4: 519-27.
7. Kumar A, Zarychanski R, Light B et al. Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group.: Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. Crit Care Med 2010; 38: 1773-85.
8. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155: 93-9.
9. Taccone FS, Laterre PF, Spapen H et al. Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Crit Care 2010; 14: R53.
10. Drusano GL, Ambrose PG, Bhavnani SM et al. Back to the future: using aminoglycosides again and how to dose them optimally. Clin Infect Dis 2007; 45: 753-60.
11. Ronco C, Ricci Z, De Backer D et al. Renal replacement therapy in acute kidney injury: controversy and consensus. Crit Care 2015; 19: 146.
12. Layeux B, Taccone FS, Fagnoul D et al. Amikacin monotherapy for sepsis caused by panresistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 2010; 54: 4939-41.
13. Levy MM, Fink MP, Marshall JC et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003; 31: 1250-6.
14. EUCAST. Aminoglycosides: EUCAST Clinical MIC Breakpoints. http:// www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_ tables/Breakpoint_table_v_4.0.pdf.
15. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008; 36: 309-32.
16. Kashuba AD, Nafziger AN, Drusano GL et al. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother 1999; 43: 623-9.
17. Prins JM, Buller HR, Kuijper EJ et al. Once versus thrice daily gentamicin in patients with serious infections. Lancet 1993; 341: 335-9.
18. Konrad F, Wagner R, Neumeister B et al. Studies on drug monitoring in thrice and once daily treatment with aminoglycosides. Intensive Care Med 1993; 19: 215-20.
19. KnausWA, Draper EA,Wagner DP et al. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818-29.
20. Vincent JL, Moreno R, Takala J et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med 1996; 22: 707-10.
21. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
22. Gálvez R, Luengo C, Cornejo R et al. Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity. Int J Antimicrob Agents 2011; 38: 146-51.
23. Duszynska W, Taccone FS, Hurkacz M et al. Therapeutic drug monitoring of amikacin in septic patients. Crit Care 2013; 17: R165.
24. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009; 37: 840-51.
25. Rea RS, Capitano B, Bies R et al. Suboptimal aminoglycoside dosing in critically ill patients. Ther Drug Monit 2008; 30: 674-81.
26. Rybak MJ, Abate BJ, Kang SL et al. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 1999; 43: 1549-55.
27. Taccone FS, de Backer D, Laterre PF et al. Pharmacokinetics of a loading dose of amikacin in septic patients undergoing continuous renal replacement therapy. Int J Antimicrob Agents 2011; 37: 531-5.
28. D'Arcy DM, Casey E, Gowing CM et al. An open prospective study of amikacin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration. BMC Pharmacol Toxicol 2012; 13: 14.
29. Prowle JR, Schneider A, Bellomo R. Clinical review: optimal dose of continuous renal replacement therapy in acute kidney injury. Crit Care 2011; 15: 207.
30. The RENAL Replacement Therapy Study Investigators. Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med 2009; 361: 1627-38.
31. Kinowski JM, de la Coussaye JE, Bressolle F et al. Multiple-dose pharmacokinetics of amikacin and ceftazidime in critically ill patients with septic multiple-organ failure during intermittent hemofiltration. Antimicrob Agents Chemother 1993; 37: 464-73.
32. Petejova N, Zahalkova J, Duricova J et al. Gentamicin pharmacokinetics during continuous venovenous hemofiltration in critically ill septic patients. J Chemother 2012; 24: 107-12.
33. Bassetti M, De Waele JJ, Eggimann P et al. Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria. Intensive Care Med 2015; 41: 776-95.
34. Hartzell JD, Neff R, Ake J et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 2009; 48: 1724-8.
35. Michalopoulos AS, Falagas ME. Colistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patients. Ann Intensive Care 2011; 1: 30.
36. Ni WT, Liang BB, Cai Y et al. A pharmacodynamic simulation to evaluate tigecycline in treatment of nosocomial pneumonia caused by multidrugresistant Acinetobacter baumannii. Pak J Pharm Sci 2014; 27: 463-7.
37. Parker S, Lipman J, Koulenti D et al. What is the relevance of fosfomycin pharmacokinetics in the treatment of serious infections in critically ill patients? A systematic review. Int J Antimicrob Agents 2013; 42: 289-93.
38. De Pascale G, Montini L, PennisiMet al. High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Crit Care 2014; 18: R90.